Sensei biotherapeutics appoints stephanie krebs, ms, mba, as chief business officer

Boston, nov. 01, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of stephanie krebs, ms, mba, as chief business officer.

SNSE Ratings Summary

SNSE Quant Ranking